Alector
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Alector and other ETFs, options, and stocks.About ALEC
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies.
ALEC Key Statistics
ALEC News
Earlier this week, Alector and its partner GSK announced that latozinemab failed to meet safety and efficacy criteria in a Phase 3 clinical trial for frontotemp...
On Tuesday, Alector, Inc. (NASDAQ:ALEC) announced results from the Phase 3 INFRONT-3 trial evaluating latozinemab (AL001) for frontotemporal dementia caused by...
Analyst Andrew Fein of H.C. Wainwright reiterated a Buy rating on Alector, reducing the price target to $5.00. Elevate Your Investing Strategy: Take advantage o...
Analyst ratings
67%
of 9 ratingsMore ALEC News
H.C. Wainwright lowered the firm’s price target on Alector (ALEC) to $5 from $10 and keeps a Buy rating on the shares. The firm removed AL001 from the stock’s v...
BTIG downgraded Alector (ALEC) to Neutral from Buy without a price target after the Phase III miss and discontinuation of the latozinemab program. The firm says...
Alector (ALEC) announced results from the Phase 3 INFRONT-3 clinical trial evaluating latozinemab in individuals with frontotemporal dementia due to a progranul...